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Abstract

Research Question

Pharmacologic advances have been made with the
development of new drug therapies that essentially cure the
hepatitis C virus, such as sofosbuvir. The purpose of this
study is to determine whether sofosbuvir should encompass a
response guided therapy treatment plan versus a standard
treatment protocol, in efforts to limit the risk of adverse
effects and to minimize the cost of treatment. The systematic
review of literature retrieved from Pub Med and Cochrane,
explored studies that compared a standard treatment protocol
of 12 weeks, in male and female adults ages 18-90 years, to
response guided therapy treatment plans based on each
individual’s sustained virologic response. Reducing the
duration of treatment will decrease the risk of adverse side
effects, and lower the cost of therapy. This information will
help practitioners guide appropriate length of HCV treatment
based on each individual patient, to ensure a sustained viral
load.

Introduction
It is now estimated in the United States alone, there are
nearly 3.9 million people suffering from chronic HCV,
with nearly 22,000 new infections yearly. There are
350,000 HCV related deaths yearly worldwide, with
approximately15,000 in the United States alone. In 2007,
the deaths associated with HCV exceeded the mortality
rates linked to AIDS. As the disease progresses there is
an increased risk of cirrhosis (Fig. 1), ascites, portal
hypertension, encephalopathy, and liver cancer
(Franciscus, 2015).

Statement of the Problem
Pharmacologic advances have been made in recent years
with the development of new drug therapies, such as,
sofosbuvir, which essential “cures” HCV by eradicating
the RNA viral load from the system. Nonetheless, these
pharmacologic remedies are costly, averaging roughly a
$1000 per pill daily, for a minimum of 12-24 weeks. In
addition, there are many side effects that affect drug
adherence such as hemolytic anemia, depression, nausea,
vomiting, or diarrhea.

Figure 1. Liver Cirrhosis

The purpose of this study was to determine whether the
pharmacologic regimen, sofosbuvir, for the management of
chronic HCV should encompass a response guided therapy
treatment plan versus a standard treatment protocol, in efforts to
limit the risk of adverse side effects and to greatly minimize the
cost of treatment.

Literature Review

• Akoth et al. (2015) stated 76% of patients on a regimen of sofosbuvir,
ledipasvir, and NS3/4A for 6 weeks. Overall 76% of patients retained
a SVR while 22% of patients experienced a viral relapse.
• Abbott et al. (2015) reported a 4 week treatment using a small
open-label nonrandomized, clinical trial that examined 25 African
American genotype 1 patients using sofosbuvir. The study showed
48% retained a SVR.
• Harris, Schwab, and Ward (2015) performed a small retrospective
observational cohort study to measure whether the previous response
guided therapy protocol was applied properly using boceprevir and
telaprevir. Of 134 patients 15% met the qualifications
for ending therapy.
Table 1. Responding During and After Treatment

Response
HCV RNA <25 IU/ml
During treatment period- no./total
no. %
At wk 2
At wk 4
After end of treatment-no. (%)
At wk 4
At wk 12
Virologic failure during treatment
Relapse in pts with HCV RNA < 25
IU/ml at end of treatment- no. (%)
Lost to follow up
Withdrew consent
N= number of patients

LDV-SOF for 8
Wk
(N=215)

LDVLDV-SOF for
SOF+RBV for 8 12 Wk
Wk (N=216)
(N=216)

190/215 (88)
215/215 (100)

195/214 (91)
211/213 (99)

197/216 (91)
216/216 (100)

207 (96)
202 (94)
0

205 (95)
201 (93)
0

208 (96)
206 (95)
0

11(5)
1
1

LDV= ledipasvir

• A standard 12 weeks of therapy could potentially be
lowered to 6 weeks in select individuals thus lowering
the treatment costs and side effects.

Magnifico, L. (2013) The facts about hepatitis c: prognosis and life expectancy. Healthline.
Retrieved from http://www.healthline.com/health-slideshow/hepatitis-prognosis-and-lifeexpectancy

• An et al. (2014) reported a SVR of 95% at 12 weeks with
sofosbuvir and ledipasvir. The SVR was 94% with sofosbuvir and
ledispavir at 8 weeks (Table 1).

9(4)
5
1
SOF= sofosbuvir

3(1)
7
0
RBV= ribavirin

An, D., Bernstein, D., Chojkier, M., Di Bisceglie, A., Ghalib, R., Gordon, S., . . . Svarovskaia, E. (2014).
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic hcv without cirrhosis. New England Journal
of Medicine, 370(20), 1883.

Applicability to Clinical
Practice

Discussion
An et al. (2014) demonstrated a high percentage of patients were
able to achieve a SVR with 8 weeks of treatment using sofosbuvir.
The authors did not include race or ethnicity as an inclusion criteria.
Race is definitely an area that needs to be explored more. The study
was also done on genotype 1 patients. Other genotypes need to be
evaluated.
Akoth et al. (2015) data suggests that 6 weeks of treatment is
effective in achieving a SVR in certain individuals. Factors such as
low viral load and early fibrosis could indicate whether the patient
should endure a shorter treatment protocol, such as 4 weeks, versus
the standard 12 weeks. However, more research should be conducted
with larger sample studies, and should include individuals with a
decompensated liver (Figure 1).

Abbott et al. (2015) acknowledged a correlation with achieving a
SVR in just 4 weeks of treatment in individuals with an HCV RNA
baseline level of less than 6 million IU/ml. The data suggests
response guided therapy may be feasible in individuals with a low
viral load, and are without cirrhosis. However they state that more
research is needed with a larger population size and race.
Harris, Schwab, and Ward (2015) suggest providers do not follow the
response guided therapy protocol properly, due to the provider’s lack
of knowledge and proper training with the treatment, and the fear of
discontinuing the drug too early. The authors state that managed care
pharmacists need to implement strategies that will aim for better
physician training and compliance with the response guided therapy
guidelines, if it were ever implemented for sofosbuvir.
The data suggests response guided therapy may be feasible in
individuals with a low viral load, and are without cirrhosis. Research
limitations include small population size, race, and viral load.
Provider knowledge is essential in response guided therapy plans, as
many providers did not follow the protocol properly and
discontinued treatment later than needed.

• It was noted there is a dire need for clinical pharmacists
to implement a better strategy to effectively train
physicians how to incorporate a response guided therapy
method based on proper guidelines. Proper training is
essential to avoid longer durations of treatment due to
lack of knowledge and training given to providers.
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